OncoCyte

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

RENO, Nev.--(BUSINESS WIRE)--Echelon Diagnostics and Oncocyte join forces to develop analytical software that can scale to support Oncocyte's clinical tests and solutions

EchelonDx and Oncocyte Announce Collaboration to Create Seamless Informatics Software to Scale Proprietary Clinical Test Offerings

Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies

Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte's DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally

OncoCyte Corporation (OCX) CEO Ronnie Andrews on Q1 2021 Results - Earnings Call Transcript

-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth -

Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update

IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results for the first quarter ended March 31, 2021, on Monday, May 17, 2021, after the close of the U.S. financial markets. The Company will host a conference call on Monday, May 17, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17

OncoCyte (OCX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will OncoCyte (OCX) Report Negative Q1 Earnings? What You Should Know

DetermaIO now shown to predict immunotherapy response in four different tissue types suggesting potential pan-cancer applicability DetermaIO now shown to predict immunotherapy response in four different tissue types suggesting potential pan-cancer applicability

Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting

Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample

Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will host a key opinion leader (KOL) call on novel biomarkers in identifying appropriate responders to immune checkpoint inhibitors on Monday, April 19, 2021 at 11:30am Eastern Time.

Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™

IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that management is scheduled to participate in a fireside chat at the 20th Annual Needham Virtual Healthcare Conference.

Oncocyte to Participate in Fireside Chat at the 20th Annual Needham Virtual Healthcare Conference

OncoCyte's pipeline of genomics-based cancer treatments bode well for its growth in the coming decade and OCX stock is already up 90% year-to-date. The post Best Stocks for 2021: OCX Got Off to a Fast Start But the Best Is Yet to Come appeared first on InvestorPlace.

Best Stocks for 2021: OCX Got Off to a Fast Start But the Best Is Yet to Come

Oncocyte Corporation (OCX) CEO Ronnie Andrews on Q4 2020 Results - Earnings Call Transcript

OncoCyte (OCX) delivered earnings and revenue surprises of 10.00% and -52.10%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OncoCyte (OCX) Reports Q4 Loss, Misses Revenue Estimates

DetermaRx commercialization momentum continues with 36% sample growth and 58% revenue growth compared to Q3 2020

Oncocyte Provides Corporate Update and Reports Fourth Quarter and Annual 2020 Financial Results

Key Opinion Leaders in Oncology and Immune-Oncology Will Help Advance Development of Company's Diagnostic and Monitoring Tests Key Opinion Leaders in Oncology and Immune-Oncology Will Help Advance Development of Company's Diagnostic and Monitoring Tests

Oncocyte Announces Formation of Medical Advisory Board

IRVINE, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will release its financial and operating results for the fourth quarter and year ended December 31, 2020, on Tuesday, March 16, 2021, after the close of the U.S. financial markets. The Company will host a conference call on Tuesday, March 16, 2021, at 4:30 pm ET / 1:30 pm PT to discuss the results along with recent corporate developments.

Oncocyte to Report Fourth Quarter and Full Year 2020 Financial Results on Tuesday, March 16

IRVINE, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, has been approved for listing on the Nasdaq Global Market. The Company's shares will continue to trade under its current symbol, “OCX,” with trading on Nasdaq expected to commence at the open of market on Monday, March 8, 2021.   Oncocyte's shares will continue to trade on the NYSE American Exchange until the close of trading on Friday, March 5, 2021.

Oncocyte to Begin Trading on the Nasdaq Stock Market on March 8, 2021

IRVINE, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, announced today that management is scheduled to participate in a Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference.

Oncocyte to Participate in Fireside Chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced the closing the sale of 8,947,000 shares of its common stock at a public offering price of $4.50 per share in its previously announced underwritten public offering, including 1,167,000 shares sold upon the exercise in full of a 15% over-allotment option by the underwriters. The gross proceeds to the Company from this offering were approximately $40.3 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company. The offering closed on February 9, 2021.

Oncocyte Announces Closing of $40 Million Public Offering of Common Stock

The announcement of a new share issue usually drives a stock's price down, after all.

Why Oncocyte Shot 13% Higher Today

IRVINE, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it has priced the previously announced underwritten public offering of 7,780,000 shares of its common stock, at a public offering price of $4.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $35.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by the Company. The offering is expected to close on or about February 9, 2021, subject to satisfaction of customary closing conditions. The Company has granted the underwriters a 30-day option to purchase up to an additional 1,167,000 shares of its common stock at the public offering price.

Oncocyte Announces Pricing of $35 Million Public Offering of Common Stock

Oncocyte Corporation (NYSE: OCX) has agreed to acquire Chronix Biomedical, a privately held molecular diagnostics company, developing blood tests for cancer treatment and organ transplants. This agreement supersedes the previous agreement announced in October 2020.

Oncocyte Acquires Blood-Based Molecular Diagnostics Provider, Chronix Biomedical For Roughly $10 Million

Transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing

Oncocyte Announces Definitive Agreement to Acquire Chronix Biomedical, Inc.

OncoCyte Corp (NYSE: OCX) shares are advancing to their highest level since the middle of 2019 on above-average volume. Oncocyte said it has entered into definitive agreements with its two largest institutional investors, namely Pura Vida Investments and Broadwood Partners, to purchase about $25 million of its common shares in a registered offering priced at $3.424 per share.

News for OncoCyte Stock (OCX)